Clinical Trials in Arizona

Showing 4641-4660 of 16,770 trials

Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

NCT00179673

Subjects who qualify will receive lenalidomide daily on days 1-21 of every 28-day cycle. Treatment will continue for up to 52 weeks or until disease progression; subjects who achieve a Complete Response (CR) will receive an additional 2 cycles of treatment prior to discontinuation. Subjects will be followed for progression free survival following discontinuation from the treatment phase

Non-Hodgkins Lymphoma

Celgene43 participantsStarted Jun 2005

Scottsdale, Arizona, United States • Berkeley, California, United States • Fountain Valley, California, United States +12 more locations

Active Not RecruitingPhase 1/242 miles

Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation

NCT03475212

The purpose of this study is to evaluate whether virus-specific T cell lines (VSTs) are safe and can effectively control three viruses (EBV, CMV, and adenovirus) in patients who have had a stem cell transplant and also in patients that have a primary immunodeficiency disorder with no prior stem cell transplant.

Cytomegalovirus InfectionsAdenovirus InfectionEBV Infection

Pediatric Transplantation & Cellular Therapy Consortium52 participantsStarted Jun 2018

Phoenix, Arizona, United States • Duarte, California, United States • Los Angeles, California, United States +27 more locations

Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation

Find Trials by Condition in Arizona

A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease

Effect of a Wide Spectrum Nutritional Supplement on Mitochondrial Function in Children With Autism Spectrum Disorder

Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)

Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors

Treatment to Lift Facial Lax Skin and Improve Facial Wrinkles Using Precise and Lift Applicators

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

Trauma Informed Guilt Reduction Therapy

Evaluating the Safety and Effectiveness of the InnAVasc Graft for Dialysis Access in Patients With Kidney Failure

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

A Study of SEA-CD40 Given With Other Drugs in Cancers

A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma

Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia

Affect Treatment for Depression and Anxiety (TAD Pilot)

Adalimumab in JIA-associated Uveitis Stopping Trial

Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.

QT Changes as Detected From LINQ ECG During Antiarrhythmic Loading (LINQ QT)

SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma